专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100251804A1 DEVICE AND PROCESS FOR RECOGNIZING A CORRECT USE OF AN ALCOHOL MEASURING DEVICE 有权
标题翻译：用于识别正确使用酒精测量装置的装置和方法
公开(公告)号：US20100251804A1
公开(公告)日：2010-10-07
申请号：US12546144
申请日：2009-08-24
申请人： Stefan Morley , Ulrich Köhler , Andreas Huth
发明人： Stefan Morley , Ulrich Köhler , Andreas Huth
IPC分类号： G01N33/497 , H04N7/18
CPC分类号： G01N33/4972 , B60K28/063 , B60W2540/24
摘要： A device and a process are provided for recognizing a correct use of an alcohol measuring device by a test subject. At least one alcohol measuring device is provided with a signal transmitter, an analysis and control unit and a camera unit. An image field of the camera unit is divided into an inner image field area and an outer image field area. The inner image field area detects at least the face area of the test subject. The camera unit records changes at a boundary between the inner image field area and the outer image field area. A signal sent by the signal transmitter in the inner image field area can be detected by the camera unit.
摘要翻译：提供了一种装置和方法，用于识别测试对象正确使用酒精测量装置。至少一个酒精测量装置具有信号发射器，分析和控制单元以及相机单元。相机单元的图像场被分成内部图像场区域和外部图像场域区域。内部图像区域至少检测测试对象的面部区域。相机单元在内部图像场区域和外部图像场区域之间的边界处记录变化。信号发送器在内部图像区域中发送的信号可由相机单元检测。

2. 发明授权

US07459470B2 N-oxide anthranylamide derivatives and their use as medicaments 失效
标题翻译： N-氧化物苯甲酰胺衍生物及其作为药物的用途
公开(公告)号：US07459470B2
公开(公告)日：2008-12-02
申请号：US10476755
申请日：2002-05-03
申请人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
发明人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
IPC分类号： A61K31/47 , C07D213/89
CPC分类号： C07D213/89 , C07D401/12 , C07D405/12
摘要： Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了取代的N-氧化邻氨基苯甲酰胺衍生物，其作为用于治疗由持续性血管生成触发的疾病的药剂的生产和用途被描述。根据本发明的化合物可以用作银屑病，卡波西肉瘤，再狭窄，子宫内膜异位症，克罗恩病，霍奇金病，白血病，牛皮癣，关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化，肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管再狭窄的抑制，血管修复术或机械装置用于保持血管开放的诸如例如作为免疫抑制剂的支架，作为无疤痕愈合的支持，老年角化病和接触性皮炎。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

3. 发明授权

US07143630B2 Gas-measuring device with an electrochemical sensor 有权
标题翻译：具有电化学传感器的气体测量装置
公开(公告)号：US07143630B2
公开(公告)日：2006-12-05
申请号：US10979540
申请日：2004-11-02
申请人： Matthias Studer , Robert Kessel , Andreas Nauber , Kathleen Leahy , Gero Sagasser , Andreas Huth
发明人： Matthias Studer , Robert Kessel , Andreas Nauber , Kathleen Leahy , Gero Sagasser , Andreas Huth
IPC分类号： G01N27/26
CPC分类号： G01N27/4163
摘要： A gas-measuring device has an electrochemical sensor and features such that the readiness for use is guaranteed for a determined period of time. A status display (7), is activated by the evaluating circuit (3) of the gas-measuring device. The status display (7) displays the degree of depletion of the sensor.
摘要翻译：气体测量装置具有电化学传感器和特征，使得使用准备在一段确定的时间内得到保证。状态显示器（7）由气体测量装置的评估电路（3）激活。状态显示（7）显示传感器的耗尽程度。

4. 发明申请

US20060167030A1 Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof 审中-公开
标题翻译：磺酰胺 - 大环化合物及其盐，包含这些化合物的药物组合物，其制备方法和用途
公开(公告)号：US20060167030A1
公开(公告)日：2006-07-27
申请号：US11312646
申请日：2005-12-21
申请人： Georg Kettschau , Hans Briem , Andreas Huth , Ulrich Luecking , Martina Schaefer , Karl-Heinz Thierauch , Wolfgang Schwede , Manfred Husemann
发明人： Georg Kettschau , Hans Briem , Andreas Huth , Ulrich Luecking , Martina Schaefer , Karl-Heinz Thierauch , Wolfgang Schwede , Manfred Husemann
IPC分类号： A61K31/519 , C07D498/04
CPC分类号： C07D513/08
摘要： The invention relates to sulfonamido-macrocycles according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling. wherein R1, R2 and R3 have the meaning as given in the specification and the claims.
摘要翻译：本发明涉及根据通式I的磺酰胺 - 大环化合物及其盐，涉及包含磺酰氨基 - 大环化合物的药物组合物以及制备磺酰氨基 - 大环化合物的方法及其用于制备用于治疗的药物组合物的用途的血管生长失调的疾病或伴随血管生成紊乱的疾病，其中所述化合物有效地干扰血管生成素并因此影响Tie2信号传导。其中R 1，R 2，R 3和R 3具有说明书和权利要求书中给出的含义。

5. 发明申请

US20060116380A1 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效
公开(公告)号：US20060116380A1
公开(公告)日：2006-06-01
申请号：US11265517
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4709 , A61K31/497 , A61K31/444 , C07D403/14 , C07D401/14
CPC分类号： C07D401/12
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

6. 发明授权

US07012081B2 Anthranyl amides and their use as medicaments 失效
标题翻译：氨基酰胺和它们作为药物的用途
公开(公告)号：US07012081B2
公开(公告)日：2006-03-14
申请号：US10275479
申请日：2001-05-07
申请人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
发明人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
IPC分类号： A61K31/47 , C07D215/00 , C07D217/00
CPC分类号： C07D213/80 , C07C237/40 , C07D211/26 , C07D211/32 , C07D211/62 , C07D217/22 , C07D265/26 , C07D309/04 , C07D309/06 , C07D317/72 , C07D401/12 , C07D405/12
摘要： Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
摘要翻译：描述了取代的邻氨基苯甲酰胺及其用作治疗由持续血管发生引起的疾病的药物及其用于制备邻氨基苯甲酰胺的中间产物。

7. 发明授权

US06878720B2 VEGF receptor tyrosine kinase inhibitors 失效
标题翻译： VEGF受体酪氨酸激酶抑制剂
公开(公告)号：US06878720B2
公开(公告)日：2005-04-12
申请号：US10180289
申请日：2002-06-26
申请人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
发明人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
IPC分类号： C07D233/64 , A61K20060101 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/415 , A61K31/417 , A61K31/44 , A61K31/4409 , A61K31/443 , A61K31/444 , A61K31/47 , A61K31/4745 , A61K31/497 , A61K31/505 , A61P20060101 , A61P17/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07C20060101 , C07C223/02 , C07C237/30 , C07C317/26 , C07D20060101 , C07D211/22 , C07D213/04 , C07D213/38 , C07D213/40 , C07D213/61 , C07D213/64 , C07D213/89 , C07D215/12 , C07D215/14 , C07D215/36 , C07D215/58 , C07D233/54 , C07D265/26 , C07D401/12 , C07D401/14 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D471/02
CPC分类号： A61K31/415 , A61K31/44 , A61K31/47 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/89 , C07D215/12 , C07D233/54 , C07D405/12
摘要： Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
摘要翻译：描述的是式（I）的化合物，其中W是O或S; X为NR8; Y为CR 9 R 10 - （CH 2）n，其中R 9和R 10彼此独立地为氢或低级烷基，n为0〜3的整数。或Y为SO2; R1是芳基; R2是包含一个环氮原子的二环杂芳基，不同的是R 2不能代表2-邻苯二酰亚氨基; R 3，R 4，R 5和R 6中的任何一个独立地为H或氢以外的取代基; 且R 7和R 8彼此独立地为H或低级烷基; 或N-氧化物或其药学上可接受的盐在制备用于治疗对VEGF受体酪氨酸激酶活性的抑制作出反应的肿瘤疾病的药物产品中的用途。式（I）化合物可用于治疗，例如，的肿瘤疾病，如肿瘤疾病，视网膜病变和年龄相关性黄斑变性。

8. 发明申请

US20050054654A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US20050054654A1
公开(公告)日：2005-03-10
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D43/02 , A61K31/497 , A61K31/501 , A61K31/506 , C07D41/02
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

9. 发明授权

US5783591A Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation 失效
标题翻译：施用恶唑烷酮和吡咯烷酮化合物治疗炎症
公开(公告)号：US5783591A
公开(公告)日：1998-07-21
申请号：US504719
申请日：1994-11-17
申请人： Walter Klose , Gerald Kirsch , Andreas Huth , Wolfgang Froehlich , Henry Laurent
发明人： Walter Klose , Gerald Kirsch , Andreas Huth , Wolfgang Froehlich , Henry Laurent
IPC分类号： A61K31/42 , A61K31/421 , A61K31/422 , C07D263/24 , C07D413/12 , A61K31/40
CPC分类号： A61K31/421 , A61K31/422 , C07D263/24 , C07D413/12 , Y10S514/886 , Y10S514/887 , Y10S514/944
摘要： Pharmaceutical preparations for the local treatment of inflammations are claimed herein, characterized in that they contain as the active ingredient one or two compounds of general Formula I ##STR1## wherein X is an oxygen atom or a methylene group, R.sub.1 and R.sub.2 represent a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally interrupted by an oxygen atom, R.sub.3 is a hydrogen atom or a hydrocarbon residue of maximally eight carbon atoms, optionally substituted by an oxo group, and R.sub.4 is a hydrogen atom or an alkyl group of maximally four carbon atoms.
摘要翻译：本文要求用于局部治疗炎症的药物制剂，其特征在于它们含有作为活性成分的一种或两种通式I的化合物（I）其中X是氧原子或亚甲基，R 1和R 2代表氢原子或最多8个碳原子的烃残基，任选被氧原子中断，R3是氢原子或最多8个碳原子的烃残基，任选被氧代基取代，R4是氢原子或最大四个碳原子的烷基。

10. 发明授权

US4894377A .beta.-carbolines and their use as medicinal agents 失效
标题翻译： β-咔啉及其作为药物的用途
公开(公告)号：US4894377A
公开(公告)日：1990-01-16
申请号：US3179
申请日：1987-01-14
申请人： Dieter Seidelmann , Ralph Schmiechen , Andreas Huth , Dieter Rahtz , Claus T. Braestrup , Mogens Engelstoft
发明人： Dieter Seidelmann , Ralph Schmiechen , Andreas Huth , Dieter Rahtz , Claus T. Braestrup , Mogens Engelstoft
IPC分类号： A61K31/404 , A61K31/435 , A61K31/437 , A61P25/00 , A61P25/08 , A61P25/18 , C07D213/40 , C07D471/04
CPC分类号： C07D471/04
摘要： .beta.-Carbolines of general Formula I ##STR1## wherein R.sup.3 is ##STR2## or --COOR", wherein R' is C.sub.1-3 alkyl or C.sub.3-6 cycloalkyl and R" is C.sub.1-4 alkyl; R.sup.4 is hydrogen, methyl, ethyl or methoxymethyl; and R.sup.A is ##STR3## wherein X is C.sub.1-12 straight-chain, branched-chain, saturated or unsaturated alkyl or a corresponding alkyl group with a CH.sub.2 -group substituted by a carbonyl group and R"" is one or more of fluorine, chlorine, bromine, or iodine, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-5 acyloxy, phenyl, C.sub.2-5 alkylenedioxy, trifluoromethyl, nitrilo, nitro or --NR.sup.IV R.sup.V wherein R.sup.IV and R.sup.V, which can be the same or different are hydrogen, C.sub.1-3 alkyl, C.sub.1-5 acyl or phenyl, or collectively with the amido nitrogen atom form a 3- to 6-membered hetero ring, which are prepared conventionally by esterifying a corresponding compound wherein R.sup.A is H or R.sup.3 is --COOH, exhibit effects on the central nervous system and can be used as psychorharmaceuticals.
摘要翻译：其中R 3是“或”-COOR“，其中R'是C 1-3烷基或C 3-6环烷基，R”是C 1-4烷基的通式I的化合物< R4是氢，甲基，乙基或甲氧基甲基; 并且RA是，其中X是C 1-12直链，支链，饱和或不饱和的烷基或具有被羰基取代的CH 2 - 的相应烷基，并且R“ 氟，氯，溴或碘，C1-3烷基，C1-3烷氧基，C1-5酰氧基，苯基，C2-5亚烷基二氧基，三氟甲基，次氮基，硝基或-NRIVRV，其中RIV和RV可以相同或不同的是氢，C 1-3烷基，C 1-5酰基或苯基，或与酰氨基氮原子一起形成3至6元杂环，其通常通过酯化相应的化合物，其中RA是H或R3是 -COOH表现出对中枢神经系统的作用，可用作精神药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式